|Bid||1.6000 x 38800|
|Ask||1.5900 x 3000|
|Day's Range||1.5100 - 1.6500|
|52 Week Range||1.0000 - 8.3500|
|Beta (5Y Monthly)||1.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
EDISON, NJ / ACCESSWIRE / November 24, 2020 / Hepion Pharmaceuticals, Inc.
\\- Interim DSMB review at the midpoint of the first dose cohort affirmed no safety or tolerability concerns with 75 mg of CRV431 in NASH patients -\\- DSMB recommended the AMBITION study continue with 225 mg CRV431 dose cohort -\\- Clinically significant reductions observed in the liver safety parameters ALT and AST -EDISON, NJ / ACCESSWIRE / November 18, 2020 / Hepion Pharmaceuticals, Inc.
EDISON, NJ / ACCESSWIRE / November 17, 2020 / Hepion Pharmaceuticals, Inc.